Best FDA-Approved GLP-1 Pill in 2026: Wegovy, Foundayo, or Rybelsus?
The 60-second answer
The best FDA-approved GLP-1 pill for most adults trying to lose weight is the Wegovy® pill (oral semaglutide 25 mg). It produced the strongest oral weight-loss result in any FDA-reviewed trial — a 13.6% mean body-weight reduction at 64 weeks. It's also the only oral GLP-1 with a heart-disease benefit on its label.
The catch: you have to take it first thing in the morning, on an empty stomach, with no more than 4 oz of water, and wait at least 30 minutes before eating, drinking, or taking other oral medications.
If that morning routine isn't realistic, Foundayo® (orforglipron) is the better pill. Take it any time of day, with or without food. The highest 17.2 mg dose produced an 11.1% weight reduction at 72 weeks in the FDA-reviewed ATTAIN-1 trial.
Rybelsus® and Ozempic® tablets (launched May 4, 2026) are real, FDA-approved oral GLP-1s — but their labels are for type 2 diabetes, not weight loss. “GLP-1 drops,” “research peptide pills,” or “compounded oral semaglutide” are not FDA-approved finished medications.
Editorial conclusions based on FDA prescribing information cited below. Not medical advice. Talk to a licensed clinician before starting any medication.
Decision shortcut
| If this is you… | Best first answer | Why |
|---|---|---|
| Want the strongest FDA-approved GLP-1 pill for weight loss + can do a morning routine | Wegovy pill | 13.6% mean weight loss in FDA-reviewed Study 7; only oral GLP-1 with cardiovascular MACE-reduction benefit on its label |
| Want a real FDA-approved GLP-1 pill but can’t do a 30-minute morning fast | Foundayo | 11.1% weight loss at 17.2 mg in ATTAIN-1; take any time, with or without food |
| Have type 2 diabetes and want an oral GLP-1 | Rybelsus or Ozempic tablets conversation | Both FDA-approved for blood sugar control and cardiovascular risk reduction in adults with T2D at high risk |
| Seeing “GLP-1 drops” or compounded oral semaglutide | Not on this page | Those are not FDA-approved finished medications |
Check eligibility for Wegovy pill or Foundayo on Ro →
Free GLP-1 Insurance Coverage Checker \u2014 no card required. Ro carries both pills on one membership, runs prior-auth paperwork, and matches manufacturer-direct cash pricing.
Prefer to compare providers? Sesame Care (sponsored affiliate link, opens in a new tab) also carries both pills, with a $59/month annual subscription as the entry point.
What We Actually Verified for This Page
Last verified: . We re-verify monthly.
- FDA prescribing information for Wegovy® tablets (Novo Nordisk, NDA 218316; PI revised May 2026)
- FDA prescribing information for Foundayo® (Eli Lilly, orforglipron)
- FDA prescribing information for Rybelsus® and Ozempic® tablets (Novo Nordisk, NDA 213051)
- Ro current pricing pages for Wegovy pill, Foundayo, and Ro Body membership
- Sesame Care medication pages and Success by Sesame subscription
- NovoCare® Pharmacy and LillyDirect® manufacturer-direct pricing
- FDA’s published statements on unapproved/compounded GLP-1 drugs
- CMS guidance on the Medicare GLP-1 Bridge program effective July 1, 2026
- Eli Lilly’s April 1, 2026 Foundayo approval announcement
- Novo Nordisk’s May 1, 2026 Ozempic tablets launch announcement
What FDA-Approved GLP-1 Pills Actually Exist in 2026
Four FDA-approved GLP-1 pills are sold in the U.S. as of May 2026: the Wegovy pill and Foundayo for weight loss, and Rybelsus and Ozempic tablets for type 2 diabetes. That is the complete list. Anything outside this list is either still in clinical trials or is a compounded product that hasn't gone through FDA review.
The two FDA-approved for weight loss
Wegovy® pill (oral semaglutide 25 mg)
- Maker
- Novo Nordisk
- FDA approval date
- December 2025
- Approved for
- Obesity (BMI 30+) or overweight (BMI 27+) with weight-related condition. Also: reducing MACE risk in adults with established cardiovascular disease + obesity/overweight.
- Trial result FDA reviewed
- 13.6% mean body-weight reduction at 64 weeks vs. 2.4% on placebo (Study 7)
Foundayo® (orforglipron)
- Maker
- Eli Lilly
- FDA approval date
- April 1, 2026 (fastest new molecular entity approval since 2002)
- Approved for
- Obesity (BMI 30+) or overweight (BMI 27+) with weight-related condition.
- Trial result FDA reviewed
- 11.1% body-weight reduction at 72 weeks vs. 2.1% on placebo at 17.2 mg (ATTAIN-1)
The two FDA-approved for type 2 diabetes (not weight loss)
Rybelsus® (oral semaglutide 3 mg, 7 mg, 14 mg)
- Maker
- Novo Nordisk
- FDA approval / launch
- September 2019
- Approved for
- Improving blood sugar control in adults with type 2 diabetes, and reducing MACE risk in adults with T2D at high risk.
Ozempic® tablets (oral semaglutide 1.5 mg, 4 mg, 9 mg)
- Maker
- Novo Nordisk
- FDA approval / launch
- U.S. launch May 4, 2026
- Approved for
- Improving blood sugar control in adults with type 2 diabetes, and reducing MACE risk in adults with T2D at high risk, including those with known heart disease.
The Full FDA-Approved GLP-1 Pill Comparison
| Wegovy pill | Foundayo | Rybelsus / Ozempic tablets | |
|---|---|---|---|
| FDA-approved for weight loss? | ✅ Yes | ✅ Yes | ❌ No (T2D only) |
| FDA-approved for type 2 diabetes? | ❌ No | ❌ No (Lilly has filed; not yet approved) | ✅ Yes |
| MACE risk-reduction benefit on label? | ✅ Yes (adults with established CV disease + obesity/overweight) | ❌ Not yet | ✅ Yes (adults with T2D at high risk) |
| Active ingredient | Oral semaglutide (peptide) | Orforglipron (small-molecule, non-peptide — first ever) | Oral semaglutide (peptide) |
| How you take it | Once daily, morning, empty stomach, ≤4 oz water, wait 30 min before food/drink/other meds | Once daily, any time, with or without food — no restrictions | Once daily, morning, empty stomach, ≤4 oz water, wait 30 min before food/drink/other meds |
| Doses available | 1.5, 4, 9, 25 mg | 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg | Rybelsus: 3, 7, 14 mg / Ozempic tablets: 1.5, 4, 9 mg |
| Trial result FDA reviewed | 13.6% body-weight reduction at 64 weeks (Study 7) | 11.1% at 72 weeks at 17.2 mg (ATTAIN-1) | Trials designed for blood sugar; not the right metric for weight-loss intent |
| Cash price (Ro) | $149/mo (1.5 mg); $199/mo (4 mg); $299/mo (9 mg, 25 mg) | $149/mo (0.8 mg); $199/mo (2.5 mg); $299/mo (5.5 mg, 9 mg); $299/mo with refill offer or $349/mo otherwise at 14.5 mg, 17.2 mg | T2D care channels; pricing varies |
| Cash price (Sesame Care) | $149/mo (1.5 mg, 4 mg); $299/mo (9 mg, 25 mg) | $149–$349/mo depending on dose | Available; T2D track |
| With commercial insurance + savings card | As low as $25/mo (eligible commercial plans only; government beneficiaries excluded) | As low as $25/mo (eligible commercial plans only; government beneficiaries excluded) | Many commercial T2D plans cover at low copay |
| Best fit for | Weight-loss seekers who can do the morning routine | Weight-loss seekers who can’t reliably do the morning routine | Adults with type 2 diabetes |
All pricing verified . Re-verify on the provider site before booking.
See current Wegovy pill and Foundayo pricing on Ro \u2192
Free GLP-1 Insurance Coverage Checker \u2014 no card required. Ro carries both pills on one membership, runs prior-auth paperwork, and matches manufacturer-direct cash pricing.
Best FDA-Approved GLP-1 Pill for Weight Loss: Wegovy Pill
The Wegovy pill is the best FDA-approved GLP-1 pill for most adults whose goal is weight loss: the strongest oral weight-loss result in any FDA-reviewed trial (13.6%), the only oral GLP-1 with a cardiovascular MACE-reduction benefit on its label, and available cash-pay from $149/month or as low as $25/month for eligible commercial-insurance patients.
Strongest FDA-reviewed weight-loss result of any oral GLP-1 sold in the U.S.
Wegovy injection’s reputation is built on 15–17% average weight loss. The pill version delivers about 13.6% in the FDA-reviewed trial — the closest oral GLP-1 to injection-grade results.
It’s actual semaglutide.
The same molecule studied across the SELECT, STEP, and SUSTAIN trials in tens of thousands of adults. We know what semaglutide does, both the good and the bad.
The label includes a heart benefit.
Wegovy is the only oral GLP-1 currently FDA-approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease who are also overweight or have obesity. That’s printed on the FDA label, not marketing copy.
Insurance coverage is more common than most people assume.
Ro’s free GLP-1 Insurance Coverage Checker scans your specific plan, tells you whether Wegovy pill is covered, what the prior authorization looks like, and what your copay would be. Two minutes. No card required.
The honest catch about the Wegovy pill
You have to take it first thing in the morning, on an empty stomach, with no more than 4 oz of water, and wait at least 30 minutes before eating, drinking, or taking any other oral medication.
Why this matters: semaglutide is a peptide that gets destroyed by stomach acid. The pill uses an absorption helper (SNAC) that creates a brief window for the drug to slip through the stomach lining. Food, coffee, juice, and other oral medications close that window.
- If you need coffee within five minutes of waking — this pill isn't for you.
- If you take levothyroxine or a proton pump inhibitor every morning — timing gets complicated.
- If your mornings are chaotic with kids, shift work, or travel — this pill will frustrate you.
Who Wegovy pill is right for
- Adult with obesity (BMI 30+) or overweight (BMI 27+) with a weight-related condition
- Morning routine is consistent enough for a 30-minute fasting window
- Prefer semaglutide (the better-studied molecule) over orforglipron
- Have heart disease or cardiovascular risk and want the MACE-reduction label benefit
Who Wegovy pill is not right for
- Take morning thyroid, reflux, or other oral meds that conflict with the timing window
- Mornings are unpredictable (early shifts, parenting young kids, frequent travel)
- History of medullary thyroid cancer, MEN 2, or pregnant/planning pregnancy
- Want a pill you can take with food — see Foundayo below
Check Wegovy pill eligibility on Ro \u2192
Free GLP-1 Insurance Coverage Checker \u2014 no card required. Ro carries both pills on one membership, runs prior-auth paperwork, and matches manufacturer-direct cash pricing.
Best FDA-Approved GLP-1 Pill If Mornings Are Chaotic: Foundayo
Foundayo (orforglipron) is the best FDA-approved GLP-1 pill for adults who want a real weight-loss medication but can't do the Wegovy pill's morning empty-stomach routine. Take it any time of day, with or without food. Its highest 17.2 mg dose produced an 11.1% body-weight reduction at 72 weeks in the FDA-reviewed ATTAIN-1 trial. Starting at $149/month cash, or as low as $25/month for eligible commercial-insurance patients with the Lilly Foundayo Savings Card.
Why Foundayo is genuinely new
Every other GLP-1 ever approved — Ozempic, Mounjaro, Wegovy injection, Zepbound, Rybelsus, the Wegovy pill — is a peptide that has to be either injected or taken with strict fasting rules. Foundayo is a small-molecule drug designed from scratch to bind to the GLP-1 receptor without being a peptide at all. No morning ritual. Take it once a day, whenever fits your schedule.
Why Foundayo can be the better fit despite slightly lower trial weight loss
Cross-trial comparisons aren't perfect — the Wegovy pill and Foundayo were never tested head-to-head, and they were tested in different patient populations over different timeframes. On paper: about 13.6% (Wegovy pill at 64 weeks) vs 11.1% (Foundayo at 17.2 mg at 72 weeks) — a real gap of roughly 2.5 percentage points.
The best pill is the pill you actually take consistently. Foundayo's no-food-restriction dosing can make it the better practical fit for people whose mornings don't accommodate the Wegovy pill routine. The flexibility is documented on the FDA label; the real-world adherence advantage follows from there.
One thing to flag with your prescriber on Foundayo
Foundayo can affect how your body absorbs other oral medications because GLP-1s slow stomach emptying. The label flags specific drug-interaction issues your prescriber will work through:
- CYP3A4 inhibitors and inducers — strong inducers can lower Foundayo blood levels. Tell your prescriber every prescription, OTC medication, and supplement you take.
- Simvastatin — a common cholesterol medication. The Foundayo label includes a dose limit when used together.
- Oral contraceptives — the label includes guidance about backup contraception during initiation and dose escalation.
- Severe hepatic (liver) impairment — discuss with your prescriber.
Who Foundayo is right for
- Mornings are unpredictable, busy, or incompatible with a 30-minute fasting window
- Take other morning oral medications and don’t want to manage timing conflicts
- Prefer flexible dosing even if the trial weight-loss number is slightly lower
- Already tried Rybelsus or another peptide oral GLP-1 and bounced off the morning protocol
Who Foundayo is not right for
- You specifically want the heart-disease MACE label benefit — Wegovy pill has it; Foundayo doesn’t yet
- You want the strongest oral weight-loss data on paper — Wegovy pill leads
- History of medullary thyroid cancer, MEN 2, or pregnant/planning pregnancy
Why Rybelsus and Ozempic Tablets Aren't the Answer for Weight Loss
Rybelsus and the new Ozempic tablets are real, FDA-approved oral GLP-1 medications — excellent options if you have type 2 diabetes. But neither is FDA-approved for weight loss. Their highest doses (14 mg for Rybelsus, 9 mg for Ozempic tablets) deliver less semaglutide than the Wegovy pill's 25 mg, so the weight-loss effect is smaller.
The cleanest way to think about it:
Wegovy pill = oral semaglutide approved for weight loss
max 25 mg; cardiovascular MACE benefit in adults with established CV disease + obesity/overweight
Rybelsus = oral semaglutide approved for type 2 diabetes
max 14 mg; cardiovascular MACE benefit in adults with T2D at high risk
Ozempic tablets = oral semaglutide approved for type 2 diabetes
max 9 mg; cardiovascular MACE benefit in adults with T2D at high risk, including those with known heart disease
When Rybelsus or Ozempic tablets are the right conversation
- You have type 2 diabetes and your prescriber wants to add an oral GLP-1 to your blood-sugar regimen.
- You have type 2 diabetes plus established heart disease, and your prescriber wants the cardiovascular MACE-reduction benefit.
- Your insurance covers semaglutide tablets for diabetes more readily than it covers Wegovy pill for weight loss.
In all of those cases, the right next step is a conversation with a clinician who treats diabetes.
What About “GLP-1 Drops,” Compounded Oral Semaglutide, or “Research Peptide” Pills?
None of those products are FDA-approved finished medications.
The FDA has stated that compounded GLP-1 drugs are not reviewed for safety, effectiveness, or quality before they are sold. We don't include them on this page because the search term you used — “best FDA-approved GLP-1 pill” — explicitly asks for products that have gone through FDA review. Compounded products haven't.
Compounded “oral semaglutide drops,” “tirzepatide lozenges,” or “GLP-1 gummies” are not the same product as Wegovy pill, Foundayo, Rybelsus, or Ozempic tablets — even if they contain a similar-sounding ingredient. Strength can vary. Absorption isn't proven. Manufacturing controls depend on the individual pharmacy. The FDA has issued multiple warning letters to companies marketing compounded products with claims that imply equivalence to FDA-approved drugs.
If you came to this page trying to figure out whether the “GLP-1 drops” you saw advertised are real: they are not what the FDA has reviewed and approved. The FDA-approved pills are Wegovy pill, Foundayo, Rybelsus, and Ozempic tablets. Everything else is something else.
What an FDA-Approved GLP-1 Pill Actually Costs in 2026
Cash-pay pricing for the Wegovy pill or Foundayo starts at $149/month for the lowest dose through Ro, NovoCare Pharmacy, LillyDirect, or Sesame Care. With commercial insurance and the manufacturer savings card, eligible patients can pay as low as $25/month. Medicare Part D beneficiaries may access both pills through the Medicare GLP-1 Bridge beginning July 1, 2026, at a $50 monthly copay, if they meet program eligibility.
The honest total monthly cost formula
Example: Wegovy pill at 1.5 mg, cash, on Ro
- · Medication: $149/month
- · Ro Body membership: $39 first month, then $74–$149/month
- · Total first month: ~$188
- · Ongoing with annual prepay: ~$223/month
Wegovy pill pricing by dose (cash-pay)
| Dose | Ro | Sesame | NovoCare Pharmacy |
|---|---|---|---|
| 1.5 mg | $149/mo | $149/mo | $149/mo through Aug 31, 2026 |
| 4 mg | $199/mo (was $149/mo through April 15, 2026) | $149/mo | $199/mo from Sept 1, 2026 |
| 9 mg | $299/mo | $299/mo | Verify current |
| 25 mg | $299/mo | $299/mo | Verify current |
Foundayo pricing by dose (cash-pay)
| Dose | Ro | Sesame | LillyDirect |
|---|---|---|---|
| 0.8 mg | $149/mo | $149/mo | $149/mo |
| 2.5 mg | $199/mo | $199/mo | $199/mo |
| 5.5 mg | $299/mo | $299/mo | $299/mo |
| 9 mg | $299/mo | $299/mo | $299/mo |
| 14.5 mg | $299/mo with 45-day refill offer; $349/mo otherwise | $349/mo | $349/mo regular; $299/mo with refill offer |
| 17.2 mg | $299/mo with 45-day refill offer; $349/mo otherwise | $349/mo | $349/mo regular; $299/mo with refill offer |
Pricing verified . Offer terms can change. Confirm on the provider's site before booking.
Insurance and the savings card
Both the Wegovy Savings Offer and the Foundayo Savings Card offer eligible commercial-insurance patients prices as low as $25/month.
- Maximum savings: $100 off one-month, $200 off two-month, $300 off three-month fills for Foundayo (similar caps for Wegovy)
- Fill limit: Up to 10 fills per year for Foundayo
- Excluded: Government beneficiaries — Medicare, Medicaid, TRICARE, VA. The savings cards cannot be used with government insurance.
Medicare GLP-1 Bridge, Medicaid, and HSA/FSA
- Medicare GLP-1 Bridge: CMS established this program for eligible Medicare Part D beneficiaries to access Foundayo and Wegovy pill beginning July 1, 2026, at a $50 monthly copay. Access depends on Part D enrollment and prior-authorization criteria.
- Medicaid: Coverage varies state by state. Some state Medicaid programs cover GLP-1s for obesity; many don't.
- HSA/FSA: Yes — both Wegovy pill and Foundayo are HSA/FSA-eligible when prescribed for the FDA-approved indications. Save your receipts.
Use Ro\u2019s free GLP-1 Insurance Coverage Checker \u2192
Free GLP-1 Insurance Coverage Checker \u2014 no card required. Ro carries both pills on one membership, runs prior-auth paperwork, and matches manufacturer-direct cash pricing.
Paying cash and don't need insurance help? Compare Sesame's flat-rate pricing (sponsored affiliate link, opens in a new tab) (subscription starts at $59/month annual).
Where to Actually Get an FDA-Approved GLP-1 Pill Online
| Ro | Sesame Care | NovoCare Pharmacy | LillyDirect | |
|---|---|---|---|---|
| Wegovy pill | ✅ | ✅ | ✅ | ❌ |
| Foundayo | ✅ | ✅ | ❌ | ✅ |
| Rybelsus / Ozempic tablets | ✅ (diabetes track) | ✅ | ✅ | ❌ |
| Free insurance coverage checker | ✅ | ❌ | ❌ | ❌ |
| Insurance concierge / prior-auth help | ✅ | Limited | ❌ | Limited |
| Membership/program fee | $39 first month, $74/mo annual, $149/mo monthly | $59/mo annual; $99/mo monthly | None | None |
| Match manufacturer-direct medication pricing | ✅ | Listed prices vary | Direct pricing | Direct pricing |
| Provider choice | Single-provider model | Pick your provider | N/A | N/A |
| Best for | First stop: pill access + insurance help | Comparison shopping; lower entry fee | Wegovy pill cash-pay, no telehealth | Foundayo cash-pay, no telehealth |
Why we recommend Ro first — three reasons, in order
It carries both Wegovy pill and Foundayo on the same membership.
The Wegovy-pill-vs-Foundayo decision often happens during the telehealth visit. On Ro, you can switch between them inside the same program without re-onboarding.
The insurance concierge actually does the paperwork.
Most telehealth providers say they “support” insurance then hand you a PDF to submit yourself. Ro’s concierge handles prior-authorization paperwork on your behalf. If you’ve ever fought a prior-auth rejection, you know how much time that saves.
The free coverage checker is genuinely free.
No card required, no commitment. You enter your plan info; it returns a medication-by-medication report including prior-auth requirements and copay estimates. Most readers think their insurance won’t cover a GLP-1 and find out it does.
Or, want provider choice and lower entry membership: See Sesame Care → (sponsored affiliate link, opens in a new tab)
When to skip telehealth entirely
If you've already picked your pill, you have insurance that covers it, and you don't need prior-auth help — manufacturer-direct can be the simplest route:
- NovoCare Pharmacy for Wegovy pill, Rybelsus, or Ozempic tablets. No membership. Wegovy pill 1.5 mg currently $149/month through August 31, 2026.
- LillyDirect for Foundayo. No membership. Free home delivery. Lowest dose $149/month self-pay; as low as $25/month with commercial insurance plus the savings card.
Side Effects and Who Shouldn't Take an FDA-Approved GLP-1 Pill
All four FDA-approved GLP-1 pills carry the same boxed warning about possible thyroid C-cell tumor risk seen in rodent studies (not established in humans), the same hard contraindication for personal or family history of MTC or MEN 2, and similar gastrointestinal side effects during dose increases. Beyond those overlaps, the specific warnings and drug-interaction issues differ pill by pill.
What's the same across all four FDA-approved pills
Hard contraindications (all 4 pills)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious allergic reaction to the active ingredient
- Currently taking another GLP-1 (don’t stack them)
Common GI side effects (all 4 pills)
- Nausea (most common during dose escalation; usually fades)
- Vomiting, diarrhea, constipation, stomach pain
- Decreased appetite (this is the intended effect)
- Burping / heartburn
What's different pill by pill
| Wegovy pill | Foundayo | Rybelsus / Ozempic tablets | |
|---|---|---|---|
| Administration timing | Morning, empty stomach, ≤4 oz water, wait 30 min before food/drink/other meds | Any time, with or without food | Morning, empty stomach, ≤4 oz water, wait 30 min before food/drink/other meds |
| Specific drug-interaction flags | Timing collision with all other oral meds; levothyroxine and PPI users need clinician sequencing | CYP3A4 inhibitors/inducers; simvastatin dose limit; oral contraceptive backup during initiation; severe hepatic impairment | Timing collision with all other oral meds; levothyroxine and PPI users need clinician sequencing |
| Nausea rate (label) | Common during dose escalation; rates published in PI | 26% at 5.5 mg, 34% at 9 mg, 35% at 17.2 mg vs 10% placebo (ATTAIN-1) | Dose-dependent; published in PI |
| MACE label benefit | Yes (adults with established CV disease + obesity/overweight) | Not yet | Yes (adults with T2D at high risk) |
Pill vs. Injection: Which Actually Works Better?
Injectable GLP-1s — particularly Zepbound (tirzepatide) and Wegovy injection (semaglutide) — produce greater average weight loss in clinical trials than any FDA-approved GLP-1 pill. Zepbound produced up to ~22% body-weight reduction; Wegovy injection ~15–17%; Wegovy pill ~13.6%; Foundayo ~11.1% at the highest dose. If maximum weight loss is your only priority, an injection is statistically more effective. The pill wins on convenience, needle aversion, no refrigeration, and discretion.
| If your priority is… | Best choice |
|---|---|
| Maximum weight loss, willing to inject | Zepbound (tirzepatide injection) |
| Strong weight loss + heart-disease label benefit, willing to inject | Wegovy injection |
| Strongest oral weight-loss data + heart-disease label benefit | Wegovy pill |
| Pill convenience + flexible daily schedule | Foundayo |
| Lowest possible cost with insurance | Whichever your specific plan covers |
One thing pills don't do better than injections: the side-effect profile. Nausea, vomiting, and the rest happen at similar rates for pill and injection patients. The pill format helps you avoid needles. It doesn't help you avoid side effects.
Wegovy pill vs. injection: full comparison →How We Picked the Best FDA-Approved GLP-1 Pill
We compared every FDA-approved GLP-1 pill sold in the U.S. on six factors weighted by what matters for someone searching “best FDA-approved GLP-1 pill”:
| Criterion | Wegovy pill | Foundayo | Rybelsus / Ozempic tablets |
|---|---|---|---|
| FDA-approved indication match (30%) | ✅ Approved for weight loss | ✅ Approved for weight loss | ❌ Not approved for weight loss |
| Label-based clinical evidence (20%) | 13.6% at 64 weeks (Study 7) | 11.1% at 72 weeks at 17.2 mg (ATTAIN-1) | Not designed for weight-loss measurement |
| Real-world dosing practicality (20%) | Morning empty-stomach routine required | Any time, with or without food | Morning empty-stomach routine required |
| Pricing/access transparency (15%) | $149–$299/mo cash-pay; $25/mo with eligible commercial savings | $149–$349/mo cash-pay; $25/mo with eligible commercial savings | Through diabetes channels; varies |
| Label safety distinctions (10%) | MACE benefit in adults with established CV disease | No MACE benefit yet | MACE benefit in adults with T2D at high risk |
| Confusion risk (5%) | Low (clearly labeled for weight loss) | Low (clearly labeled for weight loss) | High (oral GLP-1 but T2D-only) |
Verdict
Wegovy pill and Foundayo are co-leaders. The Wegovy pill edges Foundayo on raw label data and the heart benefit. Foundayo edges the Wegovy pill on dosing flexibility. The right answer for you depends on your morning routine, your cardiovascular history, and what your prescriber says fits.
Decision Path: Which FDA-Approved GLP-1 Pill Should I Ask My Prescriber About?
1. What’s your goal?
- Weight loss → continue below
- Type 2 diabetes → ask your clinician about Rybelsus or Ozempic tablets
- Both → continue, but mention diabetes during your telehealth visit
2. Can you reliably take a pill in the morning, on an empty stomach, with no more than 4 oz of water, and wait 30 minutes before eating, drinking, or taking other meds?
- Yes, every day → Wegovy pill is your best first conversation
- No, my mornings are unpredictable → Foundayo is your best first conversation
3. Do you have established heart disease (heart attack, stroke, or known cardiovascular disease)?
- Yes → Wegovy pill has the FDA-approved cardiovascular MACE-reduction benefit; ask about it specifically
- No → either pill works on this dimension
4. What’s your insurance situation?
- Commercial insurance → use Ro’s free coverage checker first; the savings card brings either pill to as low as $25/month if your plan covers it
- Medicare Part D → ask about the Medicare GLP-1 Bridge ($50 copay starting July 1, 2026, eligibility-dependent)
- Medicaid or uninsured → expect cash-pay pricing; compare Ro, Sesame, NovoCare, and LillyDirect
Routing summary
- Weight loss + can do morning routine → Wegovy pill on Ro
- Weight loss + can't do morning routine → Foundayo on Ro
- Type 2 diabetes → Rybelsus or Ozempic tablets through your prescriber
- Mixed / unsure → take our free 60-second matching quiz
Still weighing pill vs. injection, Wegovy pill vs. Foundayo, or insurance vs. cash pay?
Our free 60-second matching quiz asks about your insurance, monthly budget, injection preference, weight-loss goals, and a handful of medical-history flags. It returns a specific recommendation for the medication and provider that fit your situation.
Take the free 60-second GLP-1 matching quiz →Frequently Asked Questions
- Is there an FDA-approved GLP-1 pill for weight loss?
- Yes. Two of them. The Wegovy® pill (oral semaglutide 25 mg, FDA-approved December 2025) and Foundayo® (orforglipron, FDA-approved April 1, 2026) are both FDA-approved for chronic weight management in adults with obesity, or in adults who are overweight and have a weight-related condition.
- What is the only FDA-approved GLP-1 pill?
- There isn’t only one. As of May 2026 there are four FDA-approved GLP-1 pills sold in the U.S.: the Wegovy pill, Foundayo, Rybelsus, and Ozempic tablets (launched May 4, 2026). The first two are approved for weight loss; the last two are approved for type 2 diabetes.
- Is Foundayo better than the Wegovy pill?
- Not on every metric. The Wegovy pill produced higher mean body-weight reduction in its FDA-reviewed trial (13.6% at 64 weeks) than Foundayo did (11.1% at 72 weeks). But these are separate trials. Foundayo wins on dosing flexibility — any time, with or without food — which can make it the better practical fit if the Wegovy pill’s morning empty-stomach routine isn’t realistic for you.
- Is Rybelsus FDA-approved for weight loss?
- No. Rybelsus is FDA-approved only for type 2 diabetes — improving blood sugar control and reducing the risk of major adverse cardiovascular events in adults with T2D at high risk. The only FDA-approved oral GLP-1s for weight loss are Wegovy pill and Foundayo. Rybelsus’s maximum dose (14 mg) is lower than Wegovy pill’s (25 mg), so the weight-loss effect is meaningfully smaller.
- How much does the Wegovy pill cost without insurance?
- Without insurance: $149/month for the 1.5 mg starter dose on Ro and Sesame. The 4 mg dose on Ro is $199/month (was $149/month through April 15, 2026). The 9 mg and 25 mg maintenance doses are $299/month on Ro and Sesame. With commercial insurance and the Wegovy Savings Offer, eligible patients can pay as low as $25/month.
- How much does Foundayo cost?
- Foundayo cash pricing on Ro: $149/month at 0.8 mg, $199/month at 2.5 mg, $299/month at 5.5 mg and 9 mg, and $299/month at 14.5 mg or 17.2 mg with the 45-day refill offer (otherwise $349/month). With commercial insurance and the Lilly Foundayo Savings Card, eligible patients can pay as low as $25/month, up to 10 fills per year.
- Can you get a GLP-1 pill prescribed online?
- Yes, if a licensed clinician determines you meet the FDA-approved eligibility criteria and there’s no contraindication. Ro, Sesame Care, NovoCare Pharmacy, and LillyDirect all publish access routes for one or more of the four FDA-approved oral GLP-1s.
- Are compounded GLP-1 pills FDA-approved?
- No. The FDA has stated that compounded GLP-1 drugs are not FDA-approved finished medications and are not reviewed by the FDA for safety, effectiveness, or quality before marketing.
- Which GLP-1 pill is easiest to take every day?
- Foundayo. You take it once a day, any time, with or without food, with or without water. The other three FDA-approved oral GLP-1s — Wegovy pill, Rybelsus, and Ozempic tablets — all require morning, empty-stomach dosing with no more than 4 oz of water and a 30-minute wait before food, drink, or other oral medications.
- Do GLP-1 pills work as well as injections?
- Not on average. Injectable GLP-1s — Zepbound at up to about 22% body-weight reduction and Wegovy injection at about 15–17% — produced greater weight loss in clinical trials than oral GLP-1 pills (about 13.6% for Wegovy pill and 11.1% for Foundayo). Pills win on convenience, needle aversion, no refrigeration, and discretion.
- What’s the difference between Rybelsus and the Wegovy pill?
- Both contain oral semaglutide made by Novo Nordisk. Rybelsus is FDA-approved for type 2 diabetes at a maximum dose of 14 mg. The Wegovy pill is FDA-approved for weight loss at a maximum dose of 25 mg. The higher dose plus a different absorption-enhancing formulation gives the Wegovy pill its weight-loss-grade efficacy.
- What if I’m on Medicare?
- Medicare Part D historically excludes weight-loss medications. CMS established the Medicare GLP-1 Bridge program for eligible Part D beneficiaries to access certain GLP-1 drugs, including Foundayo and Wegovy pill, beginning July 1, 2026, with a $50 monthly copay subject to enrollment and prior-authorization criteria. The manufacturer savings cards cannot be used with Medicare or any other government insurance.
Sources Verified
- FDA prescribing information for Wegovy® tablets (Novo Nordisk, NDA 218316; PI revised May 2026)
- FDA prescribing information for Foundayo® (orforglipron, Eli Lilly, 2026)
- FDA prescribing information for Rybelsus® and Ozempic® tablets (Novo Nordisk, NDA 213051)
- Eli Lilly press release, “FDA Approves First New Molecular Entity Under National Priority Voucher Program” (Foundayo approval), April 1, 2026
- Novo Nordisk press release, Ozempic® tablets U.S. launch, May 1, 2026
- Ro Wegovy pill cost page: ro.co/weight-loss/wegovy-pill-cost
- Ro Foundayo cost page: ro.co/weight-loss/foundayo-cost
- Ro Body pricing: ro.co/weight-loss/pricing
- Ro GLP-1 Insurance Coverage Checker: ro.co/weight-loss/glp1-insurance-checker
- Sesame Care online weight loss program: sesamecare.com/service/online-weight-loss-program
- NovoCare® Pharmacy Wegovy® cost: novocare.com/patient/medicines/wegovy.html
- LillyDirect® Foundayo: lilly.com/lillydirect/medicines/foundayo
- FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”
- FDA, “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s”
- CMS, Medicare GLP-1 Bridge program guidance: cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- New England Journal of Medicine, ATTAIN-1 trial publication (orforglipron, 2026); OASIS-4 trial publication (oral semaglutide 25 mg, 2025)
About This Page
Built and maintained by The RX Index Editorial Team. The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We read FDA labels, manufacturer pricing pages, and telehealth provider product pages directly. We don't medically review medications or provide medical advice. Affiliate relationships are disclosed clearly and do not change our rankings.
| Date | Change |
|---|---|
| Initial publication. Includes Ozempic tablets (launched May 4, 2026) and the Medicare GLP-1 Bridge ($50 copay effective July 1, 2026). Pricing verified across Ro, Sesame, NovoCare, and LillyDirect. |